Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 952 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05891561RecruitingPhase 2
Short antibody treatment after surgery for early HER2+ breast cancer
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06401005RecruitingPhase 2
Radiation, chemo, and immunotherapy before surgery for triple-negative breast cancer
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
Wuhan, HubeiAges 18 years+ - NCT07610720RecruitingPhase 2
Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Guangdong, GUANGZHOUAges 18–75 - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT06711055Recruiting
Taxane plus targeted therapy for early HER2-positive breast cancer
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
Beijing, Beijing MunicipalityAges Any age - NCT06711068Recruiting
Chemotherapy plus targeted therapy for HER2+ early breast cancer
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Beijing, Beijing MunicipalityAges Any age - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT07602907RecruitingPhase 2
Low-dose paclitaxel with immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07593196Recruiting
Real-world study of her2-positive metastatic breast cancer in Kazakhstan
This study looks at real-world data from people with HER2-positive metastatic breast cancer in Kazakhstan to understand how anti-HER2 treatments (other than trastuzumab deruxtecan) are used and how well they work. If you were diagnosed between 2022 and 2023, this research may help improve future care.
Oral, KazakhstanAges 18–99 - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+ - NCT07588425Recruiting
Monitoring heart health during breast cancer treatment
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
Ankara, AnkaraAges 18 years+ - NCT07578116RecruitingPhase 3
Adding surgery and radiation for her2-positive breast cancer with a few spread spots
This trial tests whether adding surgery and radiation to the usual HER2-targeted treatment helps people with breast cancer that has spread to a few spots. You must have HER2-positive cancer that is newly spread, and you must be able to receive radiation to all tumor sites.
Jonesboro, ArkansasAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT07579286Recruiting
Skipping lymph node surgery in early breast cancer
This trial tests whether older women with early-stage, slow-growing breast cancer can safely skip removal of underarm lymph nodes during surgery. The goal is to reduce surgery-related side effects while maintaining safety.
Saint Petersburg, Russian FederationAges 60 years+ - NCT06722612Recruiting
Chemo plus targeted therapy for high-risk HER2+ early breast cancer
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
Beijing, Beijing MunicipalityAges Any age - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07570524Recruiting
Predicting Treatment Response in Early Triple-Negative Breast Cancer
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
RennesAges 18 years+ - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07563595Recruiting
Elacestrant for advanced ER+ HER2- breast cancer with ESR1 mutation
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Freiburg im BreisgauAges 18 years+ - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07543536RecruitingPhase 3
Megestrol Acetate for Fatigue in HER2+ Breast Cancer
This study tests whether a medication called megestrol acetate can help reduce severe tiredness and fatigue in people with advanced breast cancer who are receiving a targeted therapy called T-DXd (trastuzumab deruxtecan). Fatigue is a common side effect that can really impact quality of life.
Guangzhou, GuangdongAges 18–75
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 952 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.